Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent by 2019.

Global Irritable Bowel Syndrome Market 2015-2019 is a new market research publication announced by Reportstack. Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.
The analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Irritable Bowel Syndrome market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of irritable bowel syndrome.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Irritable Bowel Syndrome market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
Key Vendors
• Actavis
• Astellas Pharma
• Nestle
• Takeda Pharmaceutical
Other Prominent Vendors

• Abbott
• Alba Therapeutics
• Alfa Wassermann
• Alizyme
• Almirall
• AltheRx Pharmaceuticals
• Ardelyx 
• AstraZeneca
• Bayer 
• Bristol Myers Squibb 
• Dainippon Sumitomo Pharma
• Dong-A Socio Holdings
• Drais Pharmaceuticals
• Dynogen
• gIcare Pharma
• GlaxoSmithKline 
• Hanmi Pharmaceuticals
• ImmusanT
• Ironwood
• Janssen
• Lexicon Pharmaceuticals
• Menarini
• MicroDose Therapeutx
• Norgine
• Novartis
• Ocera Therapeutics
• Ono Pharmaceutical
• Par Pharmaceutical
• Pfizer
• Pharmos
• Protagonist Therapeutics
• RaQualia Pharma
• Rottapharm
• Salix
• Seldar Pharma
• Shire 
• SK Chemicals
• Synergy Pharmaceuticals
• Synthetic Biologics
• Tioga Pharmaceuticals
• Tsumura
• Yuhan 

Market Driver
• Presence of Unmet Need
• For a full, detailed list, view our report
Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
Market Trend
• Rise in Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Companies Mentioned
Actavis, Astellas Pharma, Nestle, Takeda Pharmaceutical, Abbott, Alba Therapeutics, Alfa Wassermann, Alizyme, Almirall, AltheRx Pharmaceuticals, Ardelyx , AstraZeneca, Bayer , Bristol Myers Squibb , Dainippon Sumitomo Pharma, Dong-A Socio Holdings,DraisPharmaceuticals, Dynogen, gIcare Pharma, GlaxoSmithKline , Hanmi Pharmaceuticals, ImmusanT, Ironwood, Janssen, Lexicon Pharmaceuticals, Menarini, MicroDose Therapeutx, Norgine, Novartis, Ocera Therapeutics, Ono Pharmaceutical, ParPharmaceutical, Pfizer, Pharmos, Protagonist Therapeutics, RaQualia Pharma, Rottapharm, Salix, Seldar Pharma, Shire , SK Chemicals, SOFAR , Synergy Pharmaceuticals, Synthetic Biologics, Tioga Pharmaceuticals, Tsumura, Yuhan
To view the table of contents and know more details please visit Global Irritable Bowel Syndrome Market 2015-2019